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ABSTRACT 
Smith-Magenis syndrome (SMS) is a type of mental retardation disorder 
associated with a deletion of DNA from chromosome 17p11.2.  It affects approximately 
18,000 individuals in the US alone. Major phenotypes are associated with a mutation in 
the Retinoic Acid-Inducible gene-1 (RAI1) and include:  developmental delay, repetitive 
behaviors, short stature, and hoarse voice. Studying the molecular mechanisms that lead 
to SMS will help promote earlier detection of the disorder and will help develop a better 
treatment plan for patients.  The purpose of this project was to characterize the promoter 
of RAI1. Studying the promoter of RAI1 will help determine the normal expression of the 
gene providing clues to its normal function and providing insight into why the lack of 
RAI1 leads to SMS.        
 The method used for characterizing promoter activity was the reporter gene assay.  
The goal of this assay was to determine if previously cloned putative promoter fragments 
contained any promoter activity.  The putative RAI1 promoter was cloned in front of the 
firefly luciferase reporter gene in the pGL3 plasmid and transiently transfected into the 
mammalian cell line HEK293.  The results we obtained suggest that the putative 
promoter fragments did not contain any promoter activity. 
 In order to identify new putative promoter fragments, 5’RLM-RACE was used on 
RNA isolated from HEK293 cells.  The purpose of the procedure was to identify the 5’ 
end of the RAI1 transcript.  If successfully cloned, the sequence of this fragment could be 
used to align with the human genome sequence and locate potential promoter elements.  
These studies are currently underway. 
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INTRODUCTION 
Smith-Magenis Syndrome. Smith-Magenis syndrome (SMS) is a type of mental 
retardation disorder associated with a deletion of DNA from chromosome 17 or a 
mutation of Retinoic Acid Inducible gene 1(RAI1).  The birth incidence rate is 
approximately 1/25,000 births. However, a higher incidence rate is suspected due to both 
under-diagnosis and misdiagnosis of SMS [1, 2].  Smith-Magenis syndrome was first 
discovered in 1986 by a group of researchers in Denver, Colorado [3].  Among those 
researchers was Dr. Elsea who has since then continued her work with SMS at the 
Medical College of Virginia in Richmond, VA.  I did this project in collaboration with 
Dr. Elsea and the members of her lab.  
Physiological Significance. There are several phenotypes associated with SMS, 
some more common than others.  The most common phenotypes can be divided into two 
groups:  major developmental/behavioral phenotypes and physical phenotypes. The most 
common developmental/behavioral phenotypes include developmental delay, repetitive 
behaviors, self-injury, sleep disturbances, and hyperactivity.  An example of a repetitive 
behavior often seen with patients with SMS is self-hugging.  The sleep disturbances seen 
are due to an inverted circadian rhythm which causes increased wakefulness at night.   
The most common physical phenotypes include short stature, hoarse voice, dental 
anomalies, and oral/motor dysfunction.  Examples of oral/motor dysfunction would 
include decrease in tongue strength and an increase in drooling. Less common 
phenotypes include seizures, heart defects, immune function abnormalities and 
renal/urinary tract abnormalities [4] [5].  In one study involving multiple patients with 
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SMS, it was found that certain phenotypes become more prominent with age.  Some of 
those phenotypes are hoarse voice, frontal prominence (large forehead), and coarsening 
of facial features  [6].   
Causes of SMS.  SMS was initially thought to be caused by a large scale alteration 
in the expression of genes in the p arm of chromosome 17. There are two possible 
mechanisms by which large scale alterations can occur.   These methods are parental 
imprinting and deletion of DNA. Parental imprinting is a type of epigenetic inheritance 
that results in only one of the two inherited alleles being expressed.  However, in an 
experiment conducted in 1991, it was found that there were no differences in phenotypes 
between both maternally and paternally derived chromosomes in SMS patients [6].  This 
evidence ruled out the possibility of parental imprinting as a mechanism for producing 
SMS [7].  Large scale deletions of DNA can occur in two ways.  Deletion may occur by 
unequal crossing over between repeated sequences producing an unbalanced DNA 
rearrangement.  Deletions can also occur spontaneously in the gonads of the parents 
therefore not affecting the parents but affecting their children [8].        
 Studies of SMS patients have defined the SMS critical interval as the common 
region on the p arm of chromosome 17 in which deletions causing the phenotypes 
associated with SMS occur.  The most common deletion is ~3.5Mb, found in about 75% 
of patients [9]. Differences in phenotype and severity may be due to the differences in 
deletion sizes and other genetic factors [7].  Smaller sized deletions are not as common 
but have allowed for the refinement of the SMS critical interval. In 2003, a group of 
researchers compressed the critical interval from 3.5 Mb to 950kb by using fluorescent in 
situ hybridization (FISH), analysis [1].  FISH analysis uses fluorescent labeling of 
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specific DNA sequences in order to determine if they are deleted or not.  If the portion of 
DNA that the probe binds to is not deleted then it will fluoresce.  If the portion of DNA is 
deleted then there will be no fluorescence. In 2005, a different group of researchers 
further compressed the critical interval to 650kb, also by using FISH [10].   
Within the 650kb critical interval, there are several candidate SMS genes (Table 
1).  DNA from patients that appear to have SMS but do not have a deletion were 
sequenced to see if any of these candidate genes were mutated.  All of these patients were 
shown to have a mutation in Retinoic Acid Inducible gene 1 (RAI1).  A mutation of the 
RAI1 gene produces a nonfunctional or truncated protein which results in 
haploinsufficiency [11] meaning that half of the amount of protein is not enough to 
produce a normal phenotype.  The majority of the features seen with SMS patients are 
now attributed to haploinsufficiency of RAI1 because RAI1 mutations or deletions have 
been found in all patients.  Other deletions on chromosome 17p11.2 may cause some of 
the less common phenotypes and contribute to phenotypic variability of SMS.  
Table 1:  Official names of genes found in the critical region on chromosome 17. 
Gene short-hand Official name of gene 
RASD1 RAS dexamethasone-induced 1 
PEMT Phosphatidylethanolamine N-
methyltransferase 
SMCR5 Smith-Magenis syndrome chromosome 
region, candidate 5 
RAI1 Retinoic acid induced 1 
SREBF1 Sterol regulatory element binding 
transcription factor 1 
TOM1L2 Target of myb 1-like 2 
ATPAF2 ATP synthase mitochondrial F1 complex 
assembly factor 2 
DRG2 Developmentally regulated GTP binding 
protein 2 
MYO15A Myosin XVA 
LLGL1 Lethal giant larvae homolog 1 
FLI1 Friend leukemia virus integration 1 
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SMCR7 Smith-Magenis syndrome chromosome 
region, candidate 7 
TOP3A Topoisomerase (DNA) III alpha 
SMCR8 Smith-Magenis syndrome chromosome 
region, candidate 8 
SHMT1 Serine hydroxymethyltransferase 1 
 
 In addition to its role in SMS, other functions of RAI1 have been identified. RAI-
1 may also play a role in schizophrenia and the age of onset of spinocerebellar ataxia 
[12].  These two roles of RAI1, along with the role of RAI1 in SMS, indicate that RAI1 
has a major effect on normal brain functioning.  Furthermore, RAI1 has been shown to 
have some anti-viral properties [13]  [14].   
In this project, the RAI1 promoter was studied.  Studying the promoter of RAI1 
will help determine the normal expression of the gene thereby providing clues to its 
normal function.  Furthermore, an understanding of the normal expression of RAI1 may 
provide insight into why the lack of RAI1 leads to SMS.  
Eukaryotic Gene Expression.  In order for an organism to express a functional 
protein from a gene, the specific DNA that encodes the protein must first be transcribed 
into mRNA and then the mRNA must be translated into a functional protein. In 
eukaryotes, there are four main steps to transcription.  They are initiation, elongation, 
termination, and post-RNA processing. Initiation is when RNA polymerase II binds to the 
promoter region of the DNA. Elongation is the process of forming the RNA transcript.  
Termination involves the release of the RNA transcript and the RNA polymerase from 
the DNA template.  Pre-RNA processing refers to further modification of the RNA 
transcript after or during transcription that is necessary for translation of the RNA into a 
protein [8].  
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This project will focus on the RAI1 promoter and the initiation of transcription.  A 
promoter is a section of DNA important in initiation of transcription because it serves as 
a recognition sequence for the attachment of the preinitiation complex.  The preinitiation 
complex that binds to the promoter region includes general transcription factors (GTFs), 
coactivators, corepressors, and RNA polymerase II [8].  There are four specific portions 
of the promoter that are of importance in the binding of GTFs and 
coactivators/corepressors.  They include the TATA box, the initiator element, the 
downstream core promoter element, and the TFIIB recognition element.  The TATA box 
is the binding site of the TATA binding protein (TBP). The initiator element directly 
overlaps the transcription start site and performs the same functions as the TATA box 
including helping with the formation of the preinitiation complex.  The downstream core 
promoter element is a seven nucleotide sequence found about 30bp downstream of the 
transcription start site.  This element is particularly important for TATA-less promoters.  
The TFIIB recognition element is a sequence specifically for the binding of TFIIB.  
Coactivators and corepressors serve to either activate or repress transcription by binding 
to certain places on the DNA [15].  
There are two general types of promoters found within cells.  They include 
promoters with a TATA-box and promoters that don’t possess a TATA-box. Although 
TBP usually binds to the TATA sequence, it can bind to the DNA in TATA-less 
promoters.  Mechanisms for binding include activator proteins to keep it in place, direct 
binding to the DNA, or the interaction of TBP with other initiatory proteins [14].  Upon 
examination of the RAI1 sequence, it was found that the promoter of RAI1 is a TATA-
less promoter.  These types of promoters usually contain more transcription initiation 
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sites and multiple binding sites for the transcription factor stimulating protein 1 (Sp1).  
The function of Sp1 is to help in the formation of the preinitiation complex.  Also 
associated with TATA-less promoters is a sequence with high G/C content.   TATA-less 
promoters do not contain a TATA box, but require other transcription binding sites in 
order to initiate transcription. The downstream core promoter element is also important in 
the binding of the preinitiation complex in TATA-less promoters.  It acts in conjunction 
with the initiator element to bind the TFIID complex of transcription factors [16]. The 
actual method of transcription initiation for TATA-less promoters varies for different 
TATA-less promoters.  A major goal of this project is to determine which of these 
elements are present in the human RAI1 promoter and their function in the expression of 
the RAI1 protein.  
Summary.  The purpose of this project is to characterize the RAI1 promoter.  The 
main methods used for characterizing the RAI1 promoter are the reporter gene assay and 
5’RLM-RACE.  The goal of the reporter gene assay is to determine if any RAI1 
fragments contain promoter activity.  The goal of 5’RLM-RACE is to determine the 5’ 
end of the RAI1 transcript.  Studying the RAI1 promoter will help determine the normal 
mechanisms for expression which may lead to insights into its role in causing Smith-
Magenis syndrome.  
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METHODS 
Cloning the 2.3kb RAI1 putative promoter construct.  The purpose of cloning the 
2.3kb RAI1 fragment was to clone the putative RAI1 promoter containing the upstream 
response element.  The predicted length of the longer putative promoter construct was 
2.3kb.  In order to clone the longer fragment of RAI1, PCR (polymerase chain reaction) 
was used to amplify the fragment from genomic DNA.  PCR was followed by gel 
electrophoresis in order to visualize the PCR product.   
 
PCR.  The reaction mix used for the PCR reaction was: 1.0µL of HEK genomic DNA, 
2.5µL of 10X PCR buffer, 1.5µL of 25mM MgCl2, 0.5µL of 10mM dNTP, 1.0 µL 
(10µM) the forward primer SHE 599F, 1.0µL (10µM) of the reverse primer DZ2R, 
17.25µL of dH20, and 0.25µL (5U/µL) of Taq DNA polymerase.  The primers were 
designed by Dr. Elsea and Dr. Zies  for the RAI1 sequence from the publicly available 
Human Genome Project.  The forward primer sequence for SHE 599F was  
5’TAAGTAGTTTGCCCAAAGCCACCC.  The reverse primer sequence for DZ2R was 
5’ACACCACACAAAGCAAGGACC. The amplification conditions for the PCR 
reaction were 94°C for 5 minutes, 40 cycles of amplification at 94°C for 1 minute, 60°C 
for 1 minute, 72°C for 3 minutes, and final extension at 72°C for 10 minutes. 
 
Gel Electrophoresis.  A 1% agarose gel was prepared by combining 600mg agarose in 
60mL of 1X TAE buffer.  The mixture was heated for approximately one minute in a 
microwave until all the agarose dissolved.  GelRed solution was added to the agarose gel 
before it hardened at 1:10,000 for visualization of the DNA.  Loading dye was added to 
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the samples at ¼ of the volume of the sample before they were applied to the gel.  A 
100bp DNA ladder was used as the marker and was added to lane one for every gel run.  
For each sample, 15-20µL was added to the other wells.  The gel ran for one hour at 100 
volts. 
 
Development of shorter RAI1 putative promoter construct.  A member of Dr. Elsea’s 
lab was able to successfully clone a small fragment of RAI1.  I was given this fragment in 
order to perform further experiments on it.  With this previously cloned fragment, I 
developed a shorter fragment in order to remove potentially problematic ATG sequences.  
It was cloned into a TOPO vector and then moved to the plasmid pGL3 (Promega, Inc.).  
The methods used for developing the shorter plasmid were:  restriction digest with the 
restriction enzyme NcoI, gel electrophoresis (as previously described), gel extraction, 
ligation, transformation, and plasmid purification. 
 
Restriction Digest with NcoI.  The following components were mixed in a 
microcentrifuge tube:  10.5µL of dH20, 2.0µL of RE 10X buffer, 2.0µL of acetylated 
BSA at 10µg/µL, and 5.0µL of DNA at 1µg/µL.  The components were mixed by 
pipetting and then 0.5µL of the restriction enzyme NcoI at 10U/µL (Promega, Inc) was 
added bringing the total volume of the reaction to 20.0µL.  The reaction was incubated 
for one hour in a 37°C water bath.   
 
Gel Extraction.  This method was performed as described in the gel extraction kit from 
Qiagen, Inc.  After gel electrophoresis, the correct DNA band was removed from the 
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agarose gel using a scalpel and then weighed in a pre-weighed 1.5mL microcentrifuge 
tube.  In order to dissolve the gel, 3 volumes of Buffer QG were added to the gel slice 
and then the gel slice was incubated in a 50°C water bath for 10 minutes with intermittent 
vortexing to aid in dissolving the gel.  After the gel slice had dissolved, one volume of 
isopropanol was added to the mixture.  DNA was bound to the spin column matrix by 
adding the mixture to a spin column, placing it inside a 2mL collection tube and 
centrifuging for 1 minute at 13,000rpm.  The bound DNA was washed by adding 0.5mL 
of Buffer QG and centrifuging for 1 minute at 13,000rpm and then adding 0.75mL of 
Buffer PE and centrifuging for an additional 1 minute at 13,000rpm.  The flow-through 
was discarded at each step and the spin column was centrifuged for an additional minute 
to dry the column.  The spin column was placed in a sterile 1.5mL microcentrifuge tube 
for elution.  The DNA was eluted by adding 50µL of elution buffer to the center of the 
spin column followed by centrifugation for 1 minute.   
 
Ligation.  The following components were mixed in a 1.5mL microcentrifuge tube:  1µL 
of gel extracted DNA, 1µL of 10X ligation buffer, 7µL of dH20, and 1µL of ligase at 
10U/µL (Promega, Inc.).  The reaction was incubated at 15°C overnight in the 
thermocycler. 
 
Transformation.  Competent DH5α cells (Invitrogen, Inc) from the -80°C freezer were 
thawed on ice before use.  Then 1µl of the ligation reaction from the previous step was 
added to the cells and gently mixed with the tip of a pipette.  The cells were incubated on 
ice for 30 minutes followed by heat shock for 20 seconds in a 42°C water bath.  The cells 
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were then placed back on ice for 2 minutes.  Preheated LB broth (950µL) was added to 
the cells and placed on a shaker for 45 minutes in a 37°C incubator.  The cells were then 
centrifuged for a few seconds in order to pellet the cells.  The majority of the supernatant 
was removed (~825µL).  The cells were resuspended in the remaining media and 100µL 
was plated on LB plus ampicillin plates using sterile technique.  The plates were 
incubated overnight at 37°C.    
                         
Plasmid Purification.  This method was performed as described in the plasmid DNA 
miniprep kit from Qiagen, Inc.  Bacterial colonies were selected from the LB-Amp plates 
from the transformation and grown in 3mL of liquid LB-Amp overnight.  The 3mL 
bacterial cultures were pelleted using a microcentrifuge and the supernatant was 
removed.  The pellet was resuspended using 250µL of resuspension buffer (Buffer P1).  
Following addition of Buffer P1, 250µL of lysis buffer (Buffer P2) was added and then 
mixed by inverting the tube.  Then, 350µL of neutralization buffer (Buffer N3) was 
added and mixed by inverting the tube.  The tubes were centrifuged for 10 minutes at 
15,682 RCF.  In order to bind the DNA, the supernatant was applied to the spin column 
and then centrifuged for 30-60 seconds.  The DNA was washed by adding 0.5mL of 
Buffer PB to the spin column and centrifuging for 1 minute and then adding 0.75mL of 
Buffer PE and centrifuging for 1 minute at 15,682 RCF.  The flow-through was discarded 
at each step and the spin column was centrifuged for an additional minute in order to dry 
the column.   In order to elute the DNA, 50µL of elution buffer was added to the center of 
the spin column that was placed in a 1.5mL microcentrifuge tube. The column was 
incubated for 1 minute at room temperature and then centrifuged for 1 minute at 15,682 
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RCF.  The concentration of the new plasmid (RAI1 short) was quantified by measuring 
the absorbance of the solution at 260nm and 280nm. 
 
Luciferase Reporter Gene Assay.  The luciferase reporter gene assay was performed on 
RAI1 long plasmid and RAI1 short plasmid in order to detect activity of the RAI1 
promoter using a luminometer.  The reporter gene constructs were transfected into 
HEK293 cells.  After 24 hours, the cells were lysed and mixed with appropriate reporter 
gene substrates.  The reporter gene activity was detected using the luminometer located at 
the Medical College of Virginia (MCV).  
 
Transient Transfection.  Three plasmids of interest were transfected into the mammalian 
cell line HEK293.  The RAI1 long (original RAI1 plasmid) and RAI1 short plasmids were 
both cotransfected with the control plasmid pSV-βgal.  Before beginning the assay, 
HEK293 cells were grown in 500µL of medium (DMEM+10%FBS without antibiotics) 
per well of a 12-well plate in order for them to be 90-95% confluent (about 0.5-2 x 10^5 
cells) at the time of transfection.  For each plasmid sample, 1.6µg of DNA was mixed 
with 100µL DMEM with no serum.  Separately, 4uL of Lipofectamine 2000 (Invitrogen, 
Inc.) was mixed with 100µL DMEM and incubated for 5 minutes.  After the 5 minute 
incubation, the diluted DNA was added to the diluted Lipofectamine 2000 bringing the 
total volume to 200µL.  The solution was mixed and incubated for 20 minutes at room 
temperature.  Then, the 200µL Lipofectamine/DNA complexes were added dropwise to 
each well containing cells.  The contents were mixed by gently rocking it back and forth 
before placing it in a 37°C CO2 incubator overnight. 
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Luciferase Cell Culture Lysis.  The transfected cells were lysed using 1X reporter lysis 
buffer (Promega).  First, the growth medium from the cells was removed using a pipette.  
Then the cells were washed with 200µL PBS (phosphate buffered saline) followed by the 
addition of 150µL of 1X lysis buffer to each well ensuring that the bottom of each well 
was covered.  The lysed cells were scraped off the bottom of the well using a scraper and 
transferred to a 1.5mL microcentrifuge tube on ice using a pipette.  Each tube was 
vortexed for 10-15 seconds and then centrifuged at 12,000 RCF for 15 seconds at room 
temperature.  The supernatant was transferred to a new tube and the cell lysates were 
stored at -80°C. 
 
Reporter Gene Assay.  First, 20µL of each prepared cell lysate was added to two wells of 
a solid white 96-well plate.  Then 100µL of steady-glo luciferase (Promega, Inc.) was 
added to half of the wells and 70µL of a 1:100 dilution of β-gal substrate (Applied 
Biosystems) and buffer mix was added to the other half of the wells.  After incubating for 
30 minutes, 100µL of the β-gal accelerator was added to the designated β-gal wells and 
activity was measured using the luminometer (Wallac 1420).  Within those 30 minutes, 
luciferase activity of the steady-glo luciferase samples was measured using the 
luminometer.  Each sample was run in duplicate. 
 
β-galactosidase Reporter Gene Assay.  The β-gal reporter gene assay was performed in 
place of the luciferase reporter gene assay in order to work out technical difficulties with 
the transient transfection assay and to use equipment available at UMW. The β-gal 
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reporter gene assay uses color change, instead of light, as an indicator of promoter 
activity. Transient transfection was performed 24 hours before beginning the β-gal 
reporter gene assay.   
  
Preparation of Lysates. Both 6-well and 12-well plates were used for growing cells for 
this assay.  The growth medium was carefully removed from the cells using a pipette.  
The cells were then washed twice with 1X PBS.  For the 6-well plate, 300µL of 1X RLB 
(reporter lysis buffer) was added to each well.  For the 12-well plate, 200µL of 1X RLB 
was added to each well.  After ensuring complete coverage of the cells by the lysis buffer, 
the cells were incubated for 15 minutes at room temperature rocking the dish every 3 
minutes.  The lysed cells were then scraped to the lower edge of the plate, transferred to a 
clean 1.5mL microcentrifuge tube using a pipette, and immediately placed on ice.  Then 
the cells were vortexed for 10-15 seconds and centrifuged in a microcentrifuge at 4°C for 
2 minutes at 15,682 RCF.  The supernatant was transferred to a new tube and stored at 
-80°C until ready to proceed to the standard assay. 
 
Standard Assay.  For the assay, 150µL of each cell lysate was transferred to a new 1.5mL 
microcentrifuge tube followed by the addition of 150µL of Assay 2X Buffer to each tube.  
The samples were mixed by vortexing them for a few seconds and then incubated at 37°C 
for 30 minutes or until the reaction turned a faint yellow color.  In order to stop the 
reactions, 500µL of 1M sodium carbonate was added to each tube.  The reactions were 
vortexed briefly before their absorbance was read at 420nm.   
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Generation of Standard Curve.  A 1:10,000 dilution stock of β-galactosidase was 
prepared in 1X RLB (reporter lysis buffer).  Using this stock, seven β-gal standards were 
made as shown in the following table.  
Table 2.  β-gal standards for the β-gal reporter gene assay. 
β-galactosidase Standard 
(milliunits) 
Volume of 1:10,000 stock 
(µL) 
Volume of 1X RLB  (µL) 
0 0 150 
1.0 10 140 
2.0 20 130 
3.0 30 120 
4.0 40 110 
5.0 50 100 
6.0 60 90 
The total volume for each standard used in the assay was 150µL.  
   
Using the same procedure as for the standard assay, 150µL of Assay 2X Buffer was 
added to each standard and incubated for 37°C for 30 minutes.  The reactions were 
stopped by adding 500µL of 1M sodium carbonate.  The reactions were vortexed briefly 
before their absorbance was read at 420nm. 
 
5’RLM-RACE.  5’RLM-RACE (Ambion, Inc.), or RNA Ligase Mediated Rapid 
Amplification of cDNA Ends, was used in order to determine the 5’ end of the RAI1 
transcript.  RNA was isolated from HEK293 cells for this procedure.   
 
Cell Lysis and RNA Isolation.  This method was performed as described in the 
RNAqueous kit by Ambion, Inc.  HEK cells were grown to confluency in a 100mm 
culture dish.  The growth medium was removed from the dish and the cells were washed 
with a 5mL of PBS.  Then, 1400µL of lysis buffer was added to the dish.  The cells were 
scraped using a scraper and two 700µL aliquots were collected in 1.5mL microcentrifuge 
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tubes.  The cell lysates were vortexed and stored at -80°C until RNA isolation was 
performed.  An equal volume of 64% ethanol was added to the lysates and mixed.  The 
lysate/ethanol mixture was added to the filter cartridge in a collection tube and then 
centrifuged for 15 seconds-1 minute at 13,000 RCF.  The previous two steps were 
repeated until all the sample had been drawn through the filter cartridge.  In order to wash 
the DNA, 700µL of wash solution #1 was applied to the filter cartridge and then 
centrifuged.  As an additional wash step, 500µL of wash solution #2/3 was applied to the 
filter cartridge and centrifuged followed by the addition and centrifugation of another 
500µL of wash solution #2/3.  In order to dry the column, the sample was centrifuged 
again.  The flow-through was discarded after each step. The first step for eluting the RNA 
was to pipet 40-60µL of preheated elution solution (about 70-80°C) to the center of the 
filter placed in a 1.5mL microcentrifuge tube and then centrifuge for 30 seconds at room 
temperature (13,000 RCF).  Then a second aliquot (10-60µL) of preheated elution 
solution was added to the center of the filter and re-spun for 30 seconds.  To complete 
RNA elution, a third 10-60µL aliquot of elution solution was added and centrifuged in 
the same manner as the first step. The RNA samples were stored at -80°C until further 
use. 
 
CIP and Termination. The purpose of treating the RNA with Calf Intestine Alkaline 
Phosphatase (CIP) is to remove the 5’ phosphate from degraded RNA.  The following 
components were mixed for the treatment with CIP step:  10µg (standard reaction) or 1µg 
(small reaction) of RNA (in XµL), 2µL of 10X CIP Buffer, 2µL of CIP, and nuclease-
free water up to 20µL.  The reaction was then mixed, centrifuged briefly, and incubated 
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for one hour at 37°C.  In order to terminate the CIP reaction, the following components 
were added to the CIP reaction:  15µL of ammonium acetate solution, 115µL of 
nuclease-free water, and 150µL of acid phenol:chloroform.  The reaction was vortexed 
thoroughly and centrifuged for 5 minutes at 15,000 RCF in a microcentrifuge.  The top 
layer (aqueous layer) was transferred to a new tube.  Then 150µL of chloroform was 
added to the sample, vortexed thoroughly, and centrifuged for 5 minutes at 15,000 RCF 
in a microcentrifuge.  The top layer (aqueous layer) was transferred to a new tube.   
 
Precipitation and Resuspension of RNA. According to the protocol from Ambion, Inc., 
the first step in precipitation of RNA was to add150µL of isopropanol to the sample, 
vortex thoroughly, and chill on ice for 10 minutes.  Then the sample was centrifuged for 
20 minutes at maximum speed in a microcentrifuge.  The pellet was washed by adding 
0.5mL cold 70% ethanol and then centrifuged for 5 minutes at 15,000 RCF.  The ethanol 
was removed carefully and the pellet was dried.  The resuspension step differed for the 
standard reaction and the small reaction.  Both of these reactions were performed and are 
differentiated below.  For the standard reaction, the pellet was resuspended in 11µL of 
Nuclease-free water.  For the small reaction, the pellet was resuspended in 4µL of 1X 
TAP Buffer.   
 
Treatment with TAP.  The purpose of the fifth step, treatment of RNA with Tobacco Acid 
Pyrophosphatase (TAP), is to remove the 5’cap from the HEK RNA.  For this step, the 
following components were mixed for the standard reaction:  5µL of CIP’d RNA, 1µL of 
10X TAP buffer, 2µL of TAP, 2µL of nuclease-free water.  The following components 
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were mixed for the small reaction:  4µL of CIP treated RNA and 1µL of TAP.  The 
reactions were then mixed, centrifuged briefly, and incubated for one hour at 37°C.   
 
Ligation of 5’RACE Adapter. The purpose of the ligation reaction is to ligate the 5’RACE 
adapter oligonucleotide to the 5’ end of the RNA.  For the standard reaction of this step, 
the following components were mixed:  2µL of CIP/TAP treated RNA, 1µL of the 
5’RACE adapter (3µg/µL), 1µL of 10X RNA ligase buffer, 2µL of T4 RNA Ligase 
(2.5U/µL), and 4µL of nuclease-free water.  The following components were mixed for 
the small reaction:  5µL of CIP/TAP treated RNA, 1µL of the 5’RACE adapter, 1µL of 
10X RNA ligase buffer, 2µL of T4 RNA ligase (2.5U/µL), and 1µL of nuclease-free 
water.  The reactions were mixed gently, centrifuged briefly, and incubated for one hour 
at 37°C. 
 
Reverse Transcription.  For the reverse transcription reaction, the following components 
were assembled in a 1.5mL microcentrifuge tube on ice:  2µL of the ligated RNA, 4µL 
10µM dNTP mix, 2µL of 50µM random decamers, 2µL of 10X RT buffer, 1µL of 
10U/µL RNase inhibitor, 1µL of M-MLV reverse transcriptase, and 8µl of nuclease-free 
water.  The reaction was mixed gently, centrifuged briefly, and incubated for one hour at 
42°C. 
 
Nested PCR for 5’RLM-RACE.  The PCR for the 5’RLM-RACE consisted of two PCR 
reactions:  an outer PCR followed by an inner PCR.  For the outer PCR, the following 
components were mixed in a PCR tube:  1µL of the reverse transcription reaction from 
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the previous step, 5µL of 10X PCR buffer, 4µL of 10µM dNTP mix, 2µL of the 5’RACE 
gene specific outer primer at 10µM (p40-5’TGCGGGTTATAATAGTCCTTGGCG), 
2µL of the 5’RACE outer primer, 36µL of nuclease-free water, and 0.25µL of 5U/µL 
thermostable DNA polymerase. The cycling profile for the PCR reaction was 94°C for 3 
minutes, 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds, 
and final extension at 72°C for 7 minutes.  For the inner PCR reaction, the following 
components were mixed in a PCR tube:  2µL of the outer PCR product, 5µL of 10X PCR 
buffer, 4µL of dNTP mix, 2µL of the 5’RACE gene specific inner primer at 10µM (p39-
5’TTCTCTAGGCGTGATGTTTCCTGC), 2µL of the 5’RACE inner primer, 35µL 
nuclease-free water, and 0.25µL of 5U/µL thermostable DNA polymerase.  The cycling 
profile for the inner PCR was the same as for the outer PCR.  Inner PCR was followed by 
gel analysis of the PCR products using gel electrophoresis as previously mentioned. 
 
TOPO Cloning.  The TOPO cloning reaction was used in order to insert the PCR product 
into a vector suitable for sequencing (Invitrogen, Inc.).  The following components were 
added together and mixed gently:  2µL of fresh PCR product, 1µL of salt solution, 2µL of 
water, and 1µL of the TOPO vector.  The reaction was incubated for 5 minutes at room 
temperature and was placed on ice before proceeding to transformation.  The TOPO 
clone was transformed using the method of transformation previously mentioned but used 
One Shot TOP10 chemically competent cells.  Following transformation, the plasmid 
was purified using the plasmid purification method previously mentioned.  After plasmid 
purification, the plasmid was sent off to AGGT, Inc. for sequencing.   
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RESULTS 
Cloning the 2.3kb RAI1 Fragment.  The purpose of cloning a longer RAI1 fragment was 
to include the potential retinoic acid response element 1 as well as additional DNA that 
may serve as part of the RAI1 promoter.  The primers used for the PCR reaction were the 
forward primer SHE599 and the reverse primer DZ2.  Primer SHE599 is located 
upstream of the putative retinoic acid response element 1 and primer DZ2 is located 
downstream of RAI1 exon 1 (Figure 1A).  Figure 1B shows a representative 1% agarose 
gel of the PCR reactions.  The experimental reactions are in lanes 2 and 3.  Multiple 
bands were seen for each sample with the largest molecular weight band at about 1000bp.  
This was not the result we were expecting since we were expecting a band at 2.3kb.     
 
Development of a Shorter RAI1 Plasmid.  The RAI1 fragment I received from MCV was 
thought to contain several ATGs, or start codons, within intron 1.  These potential start 
codons might pose a problem for the translation of the luciferase reporter gene when 
performing the reporter gene assay.  Therefore, the restriction enzyme NcoI was used to 
cut out RAI1 intron 1.  The restriction sites for NcoI are immediately upstream of intron 1 
and at the translation start site for pGL3 (Figure 2A).  Figure 2B shows a representative 
1% agarose gel of the NcoI digest.  The top band from the restriction digest is about 
6550bp.  The bottom band from the restriction digest is 326bp and represents the piece of 
DNA cut out from pGL3 (RAI1 intron 1).  Figure 2C shows a representative 1% agarose 
gel of the RAI1 long plasmid (lane 2) and the RAI1 short plasmid (lane 3) after restriction 
digest with NcoI.  Since the RAI1 short plasmid was already digested with NcoI, there 
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was only one band present at about 6550bp.  The long RAI1 plasmid had two bands 
present with the smaller band being the fragment cut out by NcoI.   
  
RAI1 Promoter Constructs.  All RAI1 promoter constructs were inserted in front of the 
luciferase gene in the pGL3 plasmid.  The RAI1 long promoter construct, containing the 
RAI1 intron 1, is shown in Figure 3A and the RAI1 short promoter construct, without 
RAI1 intron 1, is shown in Figure 3B.  The control plasmid pGL3, in which there was no 
insertion of the putative RAI1 promoter in front of the luciferase gene, is shown in Figure 
3C.   
 
Representative Data from Initial Reporter Gene Assay. The RAI1 long plasmid, RAI1 
short plasmid, and pGL3 were cotransfected with the control plasmid pSV-β-Gal.  The 
RAI1 long and RAI1 short plasmids were run in quadruplicate whereas the pGL3 plasmid 
was run in triplicate.  In addition, each sample was run in duplicate for the luciferase 
substrate and for the β-gal substrate (Table 3).  For the RAI1 long plasmid and the RAI1 
short plasmid, the β-gal numbers were higher than the luciferase numbers.   
 
β-gal Reporter Gene Assay.  The β-gal assay was run in quadruplicate with two different 
concentrations of DNA:  0µg of DNA as a control and 1µg of DNA as the experimental.  
Assay results were read on a spectrophotometer and the absorbance numbers at 420nm 
for each concentration of DNA.  As shown in Table 4, the absorbance numbers for 1µg of 
β-gal plasmid were higher than the absorbance numbers for no β-gal plasmid.   
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Reporter Gene Assay Showing No Activity.  The reporter gene assay was run with 
different concentrations of RAI1 short and RAI1 long plasmids (1µg vs. 2µg).  Each 
combination of concentration/plasmid was run in duplicate.  The light unit values for 
each plasmid/concentration combination are shown in Table 5.  In general, the β-gal 
numbers were higher than the luciferase numbers.  In addition, both the β-gal and 
luciferase numbers were consistent across the board indicating the transfection was 
working. 
 
Reporter Gene Assay with DZ23.  The reporter gene assay was run in duplicate with the 
plasmid DZ23, which has known promoter activity, the RAI1 long plasmid, RAI1 short 
plasmid, and pSV-β-gal. Table 6 shows the light unit data from each of the plasmids for 
the luciferase substrate samples and the B-gal substrate samples.  The data shows that 
plasmid DZ23 has luciferase activity whereas the other three plasmids do not have any 
luciferase activity.    
 
5’RLM-RACE. The 5’RLM-RACE protocol was used in order to amplify the 5’ end of 
RNA from RAI1. A representative 1% agarose gel from one of the two 5’RLM-RACE 
procedures conducted, is shown in Figure 5.  Lane 2 is from the outer PCR and lanes 3 
and 4 are from the inner PCR.  The bands are all less than 25bp strongly indicating they 
were excess primers and that I did not successfully amplify the 5’ end of the RAI1 
transcript.   
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Figure 1. Cloning the 2.3kb RAI1 fragment. A) Position of the primers used for cloning 
the 2.3kb fragment. The blue box represents the retinoic acid response element 1 and the 
green box represents RAI1 exon 1.  The green arrow represents the transcription start site 
for RAI1. SHE599 was the forward primer used in PCR located upstream of the Retinoic 
Acid Response Element 1.  DZ2 was the reverse primer used located directly downstream 
of RAI1 exon 1.  B) A representative agarose gel showing the PCR products.  Lane 1 is 
the DNA ladder whereas lanes 2 and 3 are the PCR product samples.     
5000 4000 3000 2000
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B) 
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Figure 2.  Development of Shorter RAI1 Plasmid.  A) NcoI restriction sites.  NcoI has two 
restriction sites represented by the red line and the red arrow.  One restriction site cuts the 
DNA at the start of RAI1 intron 1 (indicated by the thick blue line) and the second 
restriction site cuts the DNA at the translation start site for pGL3 (the red arrow).  The 
dashed lines represent pGL3.  The blue boxes within intron 1 represent possible ATGs or 
start codons for translation of RAI1.  The black arrow represents the transcription start 
site for RAI1.  B)  A representative gel following restriction digest with NcoI.  Lane 1 is 
the DNA ladder and lane 2 is the sample.  The bottom band of the sample lane is the 
DNA fragment removed from NcoI and is 326bp in length.   C) A representative gel of 
the restriction digests of RAI1 short and RAI1 long plasmids.  Lane 1 is the DNA ladder.  
Lane 2 is the restriction digest with NcoI of the RAI1 long plasmid.  Lane 3 is the 
restriction digest of RAI1 short plasmid.    
 
 
A) 
23130bp 
9416bp 
6557bp 
4361bp 
725bp 
570bp 
B) 
C) 
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Figure 3.  RAI1 Promoter Constructs.  The gray box represents the putative RAI1 
promoter.  The black box with LUC represents the luciferase gene.  A) The red line 
represents the sequence of DNA that was excised using the restriction enzyme Nco1.  
This fragment is the RAI1 long fragment.  B) This fragment is the RAI1 short fragment 
which has the red line removed.  C)  This fragment represents the control plasmid pGL3 
with no RAI1 promoter fragment inserted in front of the luciferase gene. 
 
 
 
 
 
Table 3.  Representative data of luciferase reporter gene assay using RAI1 long plasmid, 
RAI1 short plasmid, and pGL3.  
 RAI1 long plasmid RAI1 short plasmid pGL3 plasmid 
LUC 18 21 21 24 174 269 494 130 55 209 72 
32 30 28 19 167 247 453 157 40 192 67 
β-gal 611 401 323 3432 322 387 1583 288 180 495 88 
700 406 325 3526 391 474 38 27 35 487 33 
All three plasmids were cotransfected with pSV-βgal.  Quadruplets were run of the RAI1-
long plasmid and the RAI1-short plasmid.  The pGL3 plasmid was run in triplicate.   The 
first two rows represent duplicate samples that had the luciferase substrate added (LUC).  
The last two rows represent duplicate samples that had the β-gal substrate added.  All 
numbers shown are in light units (LU).   
 
 
 
 
LUC 
LUC 
A 
B 
LUC C 
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Table 4.  Representative data from the β-gal reporter gene assay.   
Amount of DNA Absorbance at 420nm 
0µg 0.141 
0.153 
0.157 
0.154 
1µg 0.269 
0.264 
0.299 
0.219 
The assay was done in quadruplet for each concentration of DNA.   
 
 
 
 
 
 
 
Table 5.  Raw data of the reporter gene assay using different concentrations of the RAI1 
short and RAI1 long plasmids.   
 1ug RAI1-long 
(LU) 
2ug RAI1-
long (LU) 
1ug RAI1-short 
(LU) 
2ug RAI1-
short (LU) 
LUC 84 86 73 58 68 87 49 
β-gal 3599 3870 2863 1710 1549 2499 2201 
Duplicates were run for each concentration/plasmid combination.     
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Table 6.  Raw data of reporter gene assay using plasmid DZ23 as a positive control 
 β-gal DZ23 RAI1 short RAI1 long 
LUC 71 85 1139 1042 76 86 61 70 
β-gal 3277 4000 3224 2991 3653 3364 3387 4354 
.  The reporter gene assay was also performed on β-gal plasmid and both RAI1 plasmid 
constructs.  All numbers shown are in light units.  Duplicates were run for each plasmid.   
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Representative 1% agarose gel of 5’RLM-RACE.  Lane 1 represents the DNA 
ladder.  Lane 2 represents the PCR product resulting from the outer PCR.  Lanes 3 and 4 
represent PCR products resulting from the inner PCR   
 
 
 
50bp 
25bp 
 27 
DISCUSSION 
Cloning the 2.3kb RAI1 Fragment.  As shown in Figure 1A, the expected length 
of the RAI1 fragment from PCR was 2.3kb.  Several attempts to clone the 2.3kb fragment 
were conducted, varying PCR conditions each time such as the concentration of MgCl2 
and the temperature cycling profile.  However, there were no bands present at 2.3kb for 
any of the attempts.  Figure 1B shows the best result that was obtained from the PCR.  
The lack of bands at 2.3kb indicates that the primers did not work in cloning the longer 
RAI1 fragment.  These data, along with additional attempts using alternative primers (not 
shown), suggest that the published sequence of the RAI1 upstream region from the human 
genome project may be inaccurate. 
Reporter Gene Assay.  The restriction digest with NcoI was successful in cutting 
out the RAI1 intron 1.  Removing RAI1 intron 1 from the RAI1 promoter construct would 
eliminate the hypothetical possibility that the start codons present in intron 1 would 
interfere with translation of the luciferase gene.  This would increase the chances of the 
reporter gene assay being successful. 
 The results from the first reporter gene assay were somewhat discouraging.  In 
general, the β-gal numbers were larger than the numbers for the luciferase samples which 
was to be expected (Table 3).  However, we were expecting numbers in the 1000s and 
10000s for both the luciferase and β-gal samples.  The luciferase sample numbers were 
generally higher for RAI1 short plasmid than for the RAI1 long plasmid.  This indicated 
that there was a possibility that the NcoI restriction digest did make a difference in the 
amount of luciferase protein produced.  The highest luciferase number was only 494 light 
units for RAI1 short plasmid and 32 light units for the RAI1 long plasmid. The low 
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luciferase numbers were attributed to a problem with the transient transfection assay 
efficiency.   
 In order to determine transfection efficiency and to use equipment available to at 
UMW, the β-gal reporter gene assay, that was spectrophotometric rather than 
luminescent, was performed.  This assay involved transfection with pSV-β-gal, cell lysis, 
and measurement of promoter activity by measuring a color change in a 
spectrophotometer.  The β-gal reporter gene assay showed higher absorbance numbers 
when pSV-β-gal plasmid was transfected versus when no pSV-β-gal was transfected 
(Table 3).  This indicated that the cells were transiently transfected, and allowed for the 
elimination of transfection as a possible source of error. Since the transfection was 
working, this suggested to us that the low luciferase numbers observed in the first 
luciferase reporter gene assay were from background noise. 
 Since the conditions for the transfection assay were worked out, another luciferase 
reporter gene assay was performed (Table 4).  Once again, the β-gal numbers were larger 
than the luciferase numbers, as expected.  When comparing the first reporter gene assay 
(Table 2) to the current attempt, the β-gal numbers were improved indicating that the 
transfection was working well.  Furthermore, the amount of plasmid transfected (1µg vs. 
2µg) did not have an effect on the degree of luminescence in the luciferase samples.  
These results further led us to believe that the luciferase activity that was detected was 
due to background noise. The presence of low luciferase activity indicated one of two 
possibilities.  There was either no promoter activity in the RAI1 promoter constructs or 
the luciferase part of the assay wasn’t working. 
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 In order to determine which of these possibilities was correct, the luciferase 
reporter gene assay was performed with plasmid DZ23 which has known promoter 
activity.  In addition, the assay was performed with RAI1 long plasmid, RAI1 short 
plasmid, and β-gal plasmid (as a control).  Plasmid DZ23 had significantly higher 
luminescence compared to the other three plasmids.  This confirmed that DZ23 has 
promoter activity, but that the two RAI1 promoter constructs do not.  Therefore, the RAI1 
fragments we used did not contain the RAI1 promoter as we initially thought.  One reason 
why we did not have any promoter activity in the RAI1 promoter constructs is that the 
sequence for the location of the 5’ end of the RAI1 gene obtained from the Human 
Genome Project (from which these constructs were derived) may be inaccurate.  If the 
sequence for the RAI1 promoter is incorrect, this would also explain why there was 
difficulty in amplifying the 2.3kb fragment.     
5’RLM-RACE. The 5’ end of the RAI1 sequence was originally obtained through 
the Human Genome Project.  However, upon investigation of the origin of the sequence, 
it was discovered that the methods used to identify the 5’ end weren’t as accurate as 
5’RLM-RACE [12].  In order to determine the true end of the RAI1 transcript, 5’RLM-
RACE, a more precise method of determining the 5’ end, was used. The 5’RLM-RACE 
protocol is also the first step in trying to determine the location of the RAI1 promoter 
experimentally.  The purpose of 5’RLM-RACE was to amplify the 5’ end of the RNA of 
RAI1.  The sequence determined from 5’RLM-RACE could then be aligned with the 
Human Genome sequence in order to develop primers to amplify the region of DNA 
directly upstream of the 5’ end.  In theory, the RAI1 promoter would be located upstream 
of the 5’ end of the RNA of RAI1 allowing for the RAI1 promoter to be successfully 
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cloned.  The results from the 5’RLM-RACE indicate that the bands present are just 
remains of the primers used.  Experiments to date were unsuccessful in amplifying the 5’ 
end of RAI1.  Time constraints prevent troubleshooting this lengthy process. 
Summary.  The purpose of this project was to characterize the RAI1 promoter 
using the reporter gene assay.  In addition to performing the reporter gene assay, I 
attempted to clone the 2.3kb fragment of RAI1.  Unfortunately, the attempts I made at 
cloning the 2.3kb fragment were unsuccessful so that portion of the project had to be 
abandoned.  I then switched to working with a fragment of RAI1 previously cloned by a 
member of Dr. Elsea’s laboratory.  I used this fragment in order to develop a shorter RAI1 
promoter construct for use in the reporter gene assay.  From the results of the multiple 
reporter gene assays that I performed, I concluded that the RAI1 promoter constructs I 
had did not contain any promoter activity.  Therefore, the RAI1 fragments that I had did 
not contain the RAI1 promoter indicating that the sequence for the RAI1 promoter is 
incorrect.  Since the fragment I was working off of was developed from the sequence of 
RAI1 from the Human Genome Project, I turned to looking at determining the location of 
the RAI1 promoter experimentally.  The first step in determining the promoter 
experimentally was 5’RLM-RACE which amplifies the 5’ end of the RNA of RAI1.  Both 
trials of 5’RLM-RACE were unsuccessful in amplifying the 5’ end.   
The experiments that I have performed throughout the course of this project have 
established a stepping stone for the next person that takes over my project.  Due to the 
work I did with the reporter gene assay, we now know that the RAI1 fragments previously 
cloned did not contain the RAI1 promoter.  Because of that finding, we can now move on 
to finding the actual location of the RAI1 promoter.             
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